Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for the treatment of peritoneal sarcomatosis

Annals of Surgical Oncology

Volumn 19, Issue 5, 2012, Pages 1410-1415

  Salti, George I ^a   Ailabouni, Luay ^a   Undevia, Samir ^b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOXORUBICIN;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURGERY; CAVITATIONAL ULTRASONIC SURGICAL ASPIRATOR; CLINICAL ARTICLE; CYTOREDUCTIVE SURGERY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY; KAPLAN MEIER METHOD; MACHINE; MALE; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PERITONEAL CANCER INDEX; PERITONEAL SARCOMATOSIS; PERITONEUM CANCER; PROGNOSIS; SCORING SYSTEM; SURGICAL INSTRUMENT; TREATMENT OUTCOME; TUMOR VOLUME; ULTRASOUND; UNIVARIATE ANALYSIS;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTHERMIA, INDUCED; INFUSIONS, PARENTERAL; MALE; MIDDLE AGED; NEOPLASM GRADING; PERITONEAL NEOPLASMS; SARCOMA; SURVIVAL RATE;

EID: 84862565067     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-012-2240-7     Document Type: Article

References (23)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277-300.
2. Jaques DP, Coit DG, Hajdu SI, Brennan MF. Management of primary and recurrent soft-tissue sarcoma of the retroperitoneum. Ann Surg. 1990;212(1):51-9. (Pubitemid 20215915)
3. Ng EH, Pollock RE, Munsell MF, Atkinson EN, Romsdahl MM. Prognostic factors influencing survival in gastrointestinal leiomyosarcomas. Implications for surgical management and staging. Ann Surg. 1992;215(1):68-77.
4. Lim SJ, Cormier JN, Feig BW, et al. Toxicity and outcomes associated with surgical cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with sarcomatosis. Ann Surg Oncol. 2007;14(8):2309-18 (Epub 2007 May 31).
5. Bilimoria MM, Holtz DJ, Mirza NQ, et al. Tumor volume as a prognostic factor for sarcomatosis. Cancer. 2002;94(9):2441-6. (Pubitemid 34457126)
6. Mudan SS, Conlon KC, Woodruff JM, Lewis JJ, Brennan MF. Salvage surgery for patients with recurrent gastrointestinal sarcoma: prognostic factors to guide patient selection. Cancer. 2000;88(1):66-74. (Pubitemid 30027680)
7. Karakousis CP, Blumenson LE, Canavese G, Rao U. Surgery for disseminated abdominal sarcoma. Am J Surg. 1992;163(6):560-4.
8. Munene G, Mack LA, Temple WJ. Systematic review on the efficacy of multimodal treatment of sarcomatosis with cytoreduction and intraperitoneal chemotherapy. Ann Surg Oncol. 2011;18(1):207-13 (Epub 2010 Aug 10).
9. Glehen O, Gilly FN, Boutitie F, et al. Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy: a multi-institutional study of 1,290 patients. Cancer. 2010;116(24):5608-18. doi:10.1002/cncr.25356.
10. Levine EA, Stewart JH 4th, Russell GB, Geisinger KR, Loggie BL, Shen P. Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy for peritoneal surface malignancy: experience with 501 procedures. J Am Coll Surg. 2007;204(5): 943-53; discussion 953-5.
11. Gusani NJ, Cho SW, Colovos C, et al. Aggressive surgical management of peritoneal carcinomatosis with low mortality in a high-volume tertiary cancer center. Ann Surg Oncol. 2008;15(3):754-63 (Epub 2007 Dec 12).
12. Rossi CR, Deraco M, De Simone M, et al. Hyperthermic intraperitoneal intraoperative chemotherapy after cytoreductive surgery for the treatment of abdominal sarcomatosis: clinical outcome and prognostic factors in 60 consecutive patients. Cancer. 2004;100(9):1943-50. (Pubitemid 38529572)
13. Ceelen WP, Flessner MF. Intraperitoneal therapy for peritoneal tumors: biophysics and clinical evidence. Nat Rev Clin Oncol. 2010;7(2):108-15 (Epub 2009 Dec 15).
14. Berthet B, Sugarbaker TA, Chang D, Sugarbaker PH. Quantitative methodologies for selection of patients with recurrent abdominopelvic sarcoma for treatment. Eur J Cancer. 1999; 35(3):413-9. (Pubitemid 29151938)
15. Baratti D, Pennacchioli E, Kusamura S, et al. Peritoneal sarcomatosis: is there a subset of patients who may benefit from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy? Ann Surg Oncol. 2010;17(12):3220-8 (Epub 2010 Jun 29).
16. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347(7):472-80. (Pubitemid 34879334)
17. DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg. 2000;231(1):51-8. (Pubitemid 30043939)
18. Gastrointestinal Stromal Tumor Meta-Analysis Group (Meta-GIST). Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients. J Clin Oncol. 2010;28(7): 1247-53 (Epub 2010 Feb 1).
19. Pisters PW, Patel SR. Gastrointestinal stromal tumors: current management. J Surg Oncol. 2010;102(5):530-8.
20. Rossi CR, Casali P, Kusamura S, Baratti D, Deraco M. The consensus statement on the locoregional treatment of abdominal sarcomatosis. J Surg Oncol. 2008;98(4):291-4.
21. Bonvalot S, Cavalcanti A, Le Péchoux C, et al. Randomized trial of cytoreduction followed by intraperitoneal chemotherapy versus cytoreduction alone in patients with peritoneal sarcomatosis. Eur J Surg Oncol. 2005;31(8):917-23. (Pubitemid 41435263)
22. Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res. 1996;82:359-74.
23. Eilber FC, Rosen G, Forscher C, Nelson SD, Dorey FJ, Eilber FR. Surgical resection and intraperitoneal chemotherapy for recurrent abdominal sarcomas. Ann Surg Oncol. 1999;6(7):645-50.